Phase 1 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), confirmed through specific imaging results, blood test findings, or a tissue biopsy
- People whose liver cancer has been identified through detailed scan results that meet certain recognised imaging classification standards (confirm with trial site for specific imaging details)
- People whose liver cancer has been identified through a blood protein marker (Alpha Fetoprotein) above a certain level, combined with suggestive scan findings
- People whose liver cancer has been confirmed through a specialised blood vessel imaging procedure or through a tissue sample
- People whose liver cancer has been assessed as suitable for a specific treatment called Y90 radioembolization (a type of targeted radiation therapy delivered through the blood vessels)
- People who have already completed standard imaging, staging, and CT scans before the research scans begin
- People aged 18 or older
- People of childbearing potential who agree to use an approved form of contraception throughout the study (and for 4 months after the research scan for men)
- People who are able to understand the study and are willing to sign a written consent form
Who may not be able to join:
- People under the age of 18
- People who have liver cancer but whose doctors have determined they are not suitable for Y90 radioembolization as a standalone treatment
- People who are pregnant or breastfeeding, due to unknown risks from the radioactive tracer used in this study
- People with poorly controlled diabetes, specifically those with a fasting blood sugar level above 200 mg/dL
- People with psychiatric conditions or personal circumstances that may make it difficult to follow the study requirements
- People who have not fully recovered from side effects of previous treatments, or who have had allergic reactions to similar substances used in this type of research
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Simone Krebs, MD, M.D. Anderson Cancer Center
Phone: (713) 563-6726
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and Adverse Events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.